In the United States, blood plasma transfusion was officially allowed for patients with COVID-19 :: Society :: RBC

Patients with coronavirus infection COVID-19 have been eligible for treatment with blood plasma transfusions from patients who have already been ill. The corresponding permission was issued by the Food and Drug Administration under the US Department of Health and Human Services. Document published on the website of the department.

“Today, the FDA has issued an emergency permit for the use of an experimental [метода] blood plasma transfusions of recovered patients for the treatment of COVID-19, ”the document says.

The specialists of the department came to the conclusion that such a method can be effective and that “its known and potential advantages outweigh the known and potential risks.” US President Donald Trump called this decision a “breakthrough” reports Assosiated Press.

According to the agency, this method of treatment has given some results, but its effectiveness is still disputed. In particular, there is a risk of side effects as well as transmission of infection.


New York Times reports over 5 million detected cases of COVID-19 in the United States

In early August, in an interview with journalist Geraldo Rivera on the air of the radio station WTAM Trump stated, which allows for the possibility of creating a vaccine against coronavirus before the US presidential elections, scheduled for November 3, 2020.

As the American president noted, many vaccines are being developed in the United States. When asked by a journalist about when the development will be completed, Trump replied that there was little to wait.

According to the latest data Johns Hopkins University, USA has the highest number of deaths due to coronavirus and those infected in the world. Since the beginning of the pandemic, 5,699,804 cases of coronavirus infection have been identified in the country. 176,765 people died.

.

Share on facebook
Facebook
Share on pinterest
Pinterest
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on email
Email

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.